He began his academic career at the National Institutes of Health (NIH), where he conducted innovative research in multiple sclerosis and immunology. In 2000, he was recruited to the Department of Neurology at the University of Rochester. That year he was awarded the prestigious Harry Weaver Neuroscience Scholar award by the National Multiple Sclerosis Society. The University of Michigan—home to one of the nation’s top neurology programs—recruited Dr. Segal to lead its Division of Multiple Sclerosis in 2007. Under Dr. Segal’s leadership, the University of Michigan became a national referral center for the treatment of patients with multiple sclerosis. The MS clinic population expanded in size from approximately 400 to 4,000 patients during his tenure.
Dr. Segal is internationally recognized for his work in multiple sclerosis (MS) and neuroimmunology. With annual NIH funding for his ongoing research programs in excess of $1.3 million, his discoveries have contributed to the basic understanding of the pathogenesis of multiple sclerosis (MS) and similar diseases. He has shown that the type of inflammation that causes damage to the nervous system during MS can vary among individuals, suggesting that pharmaceutical regimens must be personalized for each patient.
Dr. Segal has directed a number of industry- and government-sponsored clinical trials and biomarker studies that focus on individuals with relapsing and progressive forms of the disease. More recently, his laboratory is investigating how destructive immune responses in the nervous system can be skewed and redirected to initiate repair. He publishes in high impact academic journals, including the Journal of Clinical Investigation, Annals of Neurology, Proceedings of the National Academy of Sciences of the United States of America, and Lancet Neurology.
Dr. Segal has received innumerable awards, lectured nationally and internationally and served on multiple NIH study sections, including co-chairing the major review panel in his field. He holds several patents and is a member of every major organization in neurology. Dr. Segal served as Program Chair for the annual meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) between 2016 and 2018, and he currently serves as a Director at ACTRIMS. Through ACTRIMS, he has developed an annual national symposium to educate neurology residents and young research investigators about the diagnosis, pathogenesis, and treatment of MS. He was inducted into the University of Michigan League of Research Excellence in 2014. He was a Senior Scholar of the A. Alfred Taubman Medical Research Institute and has been named among the Best Doctors in America for the past eight years.
For details covering his publications, visit: https://wexnermedical.osu.edu/neurological-institute/researchers/benjamin-segal-md
Dr. Christopher-Stine graduated Cum Laude with a B.A. in chemistry from Franklin and Marshall College; was elected to Alpha Omega Alpha at Hahnemann University School of Medicine, where she received her MD degree, and she attained her Master of Public Health degree from the Johns Hopkins Bloomberg School of Public Health. Her internship and residency training in Internal Medicine were completed at MCP Hahnemann University, where she also served as Chief Resident. Soon after, she pursued a rheumatology fellowship training at Johns Hopkins. She joined the faculty of the Division of Rheumatology at Johns Hopkins in 2003.
As a clinician scientist, she utilizes the Myositis Database developed by her and her colleagues for which she is the Principal Investigator, currently numbering well over 2,000 patients recruited worldwide. She has a strong interest in patient-reported outcomes and has been the co-chair of an international effort through the OMERACT organization to develop a novel patient reported outcome measure.
Dr. Hendren's research focuses on measuring and improving the quality of care for colorectal cancer. She also participates in research to better understand and reduce short and long-term surgical complications, and research on racial and socioeconomic disparities in American cancer care. Dr. Hendren has been involved with the Michigan Surgical Quality Collaborative since 2010 where she leads the Colorectal Cancer Project.
Dr. Winter has a basic research lab that is funded by the American Cancer Society and the NIH, where he studies molecular aspects of pancreatic cancer. His special areas of research interest include developing new targeted therapies, understanding pancreatic cancer metabolism, early detection of pancreatic cancer and deciphering a biologic cause of pancreatic cancer-associated depression.
He received his undergraduate degree in Chemistry from Princeton University and attended the Weill Medical College of Cornell University. He trained in General Surgery at Johns Hopkins, and spent additional years as a post-doctoral research fellow in Oncology. Dr. Winter received specialty fellowship training in Surgical Oncology at the Memorial Sloan-Kettering Cancer Center. In 2011, Dr. Winter was recruited as an Assistant Professor of Surgery at Thomas Jefferson University and was promoted to Associate Professor in 2014 where he served as a Co-Director of the Jefferson Pancreas, Biliary and Related Cancer Center and the GI Multidisciplinary Group in the Sidney Kimmel Cancer Center.
His clinical and research interests include Dupuytren’s contracture, distal radius fractures and their surgical treatment, the surgical treatment of arthritis afflicting the hand and wrist, and upper extremity nerve injury, compression and surgery. Lastly, he’s the director for the Harvard Hand and Upper Extremity Surgery Fellowship.
He co-founded University Hospital’s cochlear implant program and he and his team have performed over 1,000 cochlear implant surgeries, making it one of the largest programs in the country. His clinical career has been devoted to the management of hearing loss, chronic ear diseases, vertigo and other otological and neurological issues. His intense research interest in the pathogenesis of Meniere’s disease has been funded by numerous agencies including the National Institutes of Health and the Deafness Research Foundation.